General Information of Drug (ID: DMQM9S0)

Drug Name
Palivizumab
Synonyms Synagis; Abbosynagis (TN); Palivizumab (INN); Palivizumab (genetical recombination); Synagis (TN); Palivizumab (genetical recombination) (JAN)
Indication
Disease Entry ICD 11 Status REF
Respiratory syncytial virus infection 1C80 Approved [1]
Therapeutic Class
Antiviral Agents
Drug Type
Monoclonal antibody
Sequence
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKD
YNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 18 - 20 days (in adults) [2]
Metabolism
The drug is metabolized via opsonization via the reticuloendothelial system []
Cross-matching ID
DrugBank ID
DB00110
TTD ID
D0A1AS

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Respiratory syncytial virus protein F (RSV F) TT57ID8 FUS_HRSVA Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.